TWI730027B - 稠合四環化合物及其組合物與用途 - Google Patents

稠合四環化合物及其組合物與用途 Download PDF

Info

Publication number
TWI730027B
TWI730027B TW106100215A TW106100215A TWI730027B TW I730027 B TWI730027 B TW I730027B TW 106100215 A TW106100215 A TW 106100215A TW 106100215 A TW106100215 A TW 106100215A TW I730027 B TWI730027 B TW I730027B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pyrrolo
mmol
Prior art date
Application number
TW106100215A
Other languages
English (en)
Chinese (zh)
Other versions
TW201726681A (zh
Inventor
凱西 卡麥隆 摩可摩斯
麥可 H 薩瑞諾－吳
喬瑟夫 P 維卡
Original Assignee
美商泰博生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商泰博生物科技股份有限公司 filed Critical 美商泰博生物科技股份有限公司
Publication of TW201726681A publication Critical patent/TW201726681A/zh
Application granted granted Critical
Publication of TWI730027B publication Critical patent/TWI730027B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106100215A 2016-01-04 2017-01-04 稠合四環化合物及其組合物與用途 TWI730027B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662274640P 2016-01-04 2016-01-04
US62/274,640 2016-01-04

Publications (2)

Publication Number Publication Date
TW201726681A TW201726681A (zh) 2017-08-01
TWI730027B true TWI730027B (zh) 2021-06-11

Family

ID=59226993

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106100215A TWI730027B (zh) 2016-01-04 2017-01-04 稠合四環化合物及其組合物與用途

Country Status (8)

Country Link
US (2) US10059718B2 (cg-RX-API-DMAC10.html)
EP (1) EP3400228B1 (cg-RX-API-DMAC10.html)
JP (1) JP7068185B2 (cg-RX-API-DMAC10.html)
CN (1) CN108779123B (cg-RX-API-DMAC10.html)
AU (1) AU2017205320B2 (cg-RX-API-DMAC10.html)
ES (1) ES2915901T3 (cg-RX-API-DMAC10.html)
TW (1) TWI730027B (cg-RX-API-DMAC10.html)
WO (1) WO2017120164A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof
CN107879989B (zh) * 2017-11-29 2020-01-03 重庆市中药研究院 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法
BR112023013722A2 (pt) * 2021-01-11 2024-01-30 Tabomedex Biosciences Inc Compostos quadracílicos fundidos, composições e usos dos mesmos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040487A2 (en) 2000-11-16 2002-05-23 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as gaba a receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521534A (en) 1983-12-19 1985-06-04 Ayerst, Mckenna & Harrison, Ltd. Imidazo[2,1-a]pyrrolo[2,1-c][1,4]benzodiazepine derivatives, methods of preparation and use
US4596799A (en) 1985-01-29 1986-06-24 Ciba-Geigy Corporation 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
US20160066387A1 (en) * 2013-03-22 2016-03-03 Lifi Labs Inc Color selection
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040487A2 (en) 2000-11-16 2002-05-23 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as gaba a receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAO, A. U. et al., "Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 ( MK 2) inhibitors", Bioorganic & medicinal chemistry letters, vol. 22, no. 2, (20120115), pages 1068 - 1072 *

Also Published As

Publication number Publication date
CN108779123A (zh) 2018-11-09
ES2915901T3 (es) 2022-06-27
US10059718B2 (en) 2018-08-28
AU2017205320B2 (en) 2021-06-24
EP3400228A4 (en) 2019-08-14
US20170190713A1 (en) 2017-07-06
EP3400228A1 (en) 2018-11-14
TW201726681A (zh) 2017-08-01
JP7068185B2 (ja) 2022-05-16
US10562909B2 (en) 2020-02-18
WO2017120164A1 (en) 2017-07-13
JP2019501971A (ja) 2019-01-24
CA3010213A1 (en) 2017-07-13
EP3400228B1 (en) 2022-04-13
CN108779123B (zh) 2025-08-19
AU2017205320A1 (en) 2018-07-05
US20180319809A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
AU2021264916B2 (en) Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
EP3968999B1 (en) Fgfr inhibitors and methods of use thereof
CN110167560B (zh) 四环素化合物和治疗方法
CN120712271A (zh) 作为kras g12d抑制剂的新型三环化合物及其用途
JP2025536369A (ja) Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用
KR20170031669A (ko) 치환된 우레아 유도체 및 이의 약제학적 용도
CN111527090B (zh) 作为p2x3抑制剂的吡唑并-吡咯并-嘧啶-二酮衍生物
CN103492384A (zh) 作为trk抑制剂的化合物和组合物
WO2023250156A1 (en) 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
CN108779123B (zh) 稠合四环化合物、其组合物和用途
CN120769855A (zh) 4-氨基吡咯并[2,1-f][1,2,4]三嗪及其制备和用途
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
HK40006173A (en) Fused quadracyclic compounds, compositions and uses thereof
HK40006173B (en) Fused quadracyclic compounds, compositions and uses thereof
WO2025231261A1 (en) Bicyclic and heterocyclic amide compounds
TW202515566A (zh) Ｓｍａｒｃａ２降解劑及其用途
CN117980290A (zh) 氰基吡啶和氰基嘧啶bcl6降解剂
HK40030438A (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors